Optimising VEGFR-TKIs (MKIs) in Differentiated Thyroid Cancer
Optimising VEGFR-TKIs (MKIs) in Differentiated Thyroid Cancer
Dr. Jaume Capdevila, Dr. Rachel van Leeuwaarde
Podcast with Dr. Jaume Capdevila and Dr. Rachel van Leeuwaarde discussing the use of multi-kinase inhibitors (MKIs), in particular VEGFR-TKIs in patients with radioactive iodine refractory differentiated thyroid cancer (DTC).
Dr. Jaume Capdevila
Medical Oncologist
Vall d'Hebron University Hospital and Vall d'Hebron Institute of ...
Spain
Dr. Rachel van Leeuwaarde
Endocrinologist
University Medical Centre Utrecht
Netherlands
Podcast | 
20 min
|
Aug 2021
This programme was made for you: your opinion matters
Share your feedback in just 4 clicks and help us to continue to create the content you need.
I agree that this educational programme:
In this episode, the two experts discuss key trials (SELECT, DECISION and COSMIC-311) and efficacy parameters of the current VEGFR-TKIs (lenvatinib, sorafenib and cabozantinib), how to manage toxicity whilst trying to optimise treatment outcomes and preserving always patients’ quality of life. They also discuss treatment strategies, when to start systemic treatment, which drug should be used first and how to sequence therapies. To close the podcast they take a look at ongoing clinical trials with other treatments in development for DTC.
This NET CONNECT podcast series is also available on Castos, Spotify, Apple Podcasts, and Google Podcasts.
NET CONNECT is an initiative of COR2ED, supported by an Independent Educational Grant from Ipsen and from Eisai Europe Limited.
Other programmes of interest
28 min
Other programmes developed by Dr. Jaume Capdevila
Dr. Jaume Capdevila
Medical Oncologist
Vall d'Hebron University Hospital and Vall d'Hebron Institute of ...
Spain
Other programmes developed by Dr. Rachel van Leeuwaarde
Dr. Rachel van Leeuwaarde
Endocrinologist
University Medical Centre Utrecht
Netherlands
